Dr. Bobak Parang Announced as Recipient of Rising Tide/LUNGevity Research Award for Overcoming Drug Resistance

$600K+ investment leverages combination of FDA approved treatments to overcome drug resistance in EGFR-positive lung cancer WASHINGTON, Oct. 28, 2026 /PRNewswire/ -- A groundbreaking clinical trial aimed at overcoming drug resistance in EGFR-positive non-small cell lung cancer (NSCLC),...

Read the full story at LUNGevity Foundation via PR Newswire (opens in a new tab)

Headline and summary from LUNGevity Foundation via PR Newswire; the full story is on the publisher's site. Nothing here is investment advice.